leisure time -WSS

leisure time

author：fashion 2025-10-01 20:13:54 - browse：71

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Eli Lilly’s Mounjaro succeeds in second weight

WSS

How to fix the rural physician shortage in the U.S.

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Medicare inequities exacerbate Puerto Rico’s health disparities

Xenotransplantation trials will require adjusting expectations, experts say

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Wikipedia

leisure time

knowledge

At least 13 dead in Texas as scorching temps continue

New documents shed light on MD Anderson Cancer Institute feud

Apple is now the first public company to be valued at $3 trillion

FDA approves first new drug developed for postpartum depression

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Virginia high school admissions case could be legal follow

R1 RCM gets $5.8 billion buyout offer from private equity firm

Apple is now the first public company to be valued at $3 trillion

Xenotransplantation trials will require adjusting expectations, experts say

hotspot

Can medical device makers keep up in the race to treat obesity?

Inside the rise of 'mukbang' eating videos

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Novo: Oral version of Ozempic leads to 15% weight loss

Millions may soon lose Medicaid when they don't have to

Wikipedia

hotspot

knowledge

knowledge